Private Company Director’s Directors to Watch 2025 highlights 31 significant and diverse directors who have contributed to and will continue to expand ongoing dialogue on board best practices and corporate governance excellence.
Modestus Obochi
Temprian Therapeutics
Modestus (Modi) Obochi, Ph.D., MBA, is a seasoned executive with more than 30 years of leadership in the biotechnology and pharmaceutical industries, driving revenue growth and operational excellence. He has held pivotal roles at organizations such as Sernova Biotherapeutics, Baxter, Pfizer Inc., Hospira and QLT, managing portfolios valued at up to $7 billion and leading global strategy. Obochi has successfully closed strategic transactions worth over $7 billion and raised substantial capital for companies.
Currently, Obochi serves as a director of Temprian Therapeutics, an investment advisor of 2Flo Ventures and a strategic advisor of Peqish Food Co.
His governance expertise includes strategy development, stakeholder engagement and operational efficiency. A visionary leader and accomplished scientist, Obochi has published extensively and holds a Ph.D. in immunology and an MBA in strategic management.
Strategic governance excellence demands visionary leadership: “Company executives and directors face varying challenges, including navigating economic volatility, fostering innovation and ensuring regulatory compliance — all while growing shareholder value. A solid approach emphasizes aligning governance frameworks with long-term strategy, fostering robust decision-making processes and leveraging diverse perspectives for proactive solutions. By integrating data-driven insights with collaborative leadership, boards can effectively balance short-term performance with sustainable growth. Success lies in a commitment to transparency, adaptability and stakeholder engagement —empowering boards to not only respond to challenges but transform them into strategic advantages.”